Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Zhejiang Dayang Biology Technology Co., Ltd. specializes in the production of bio-based chemicals, particularly focusing on amino acids and other biochemical products. The company operates primarily in China, leveraging its advanced production facilities to cater to both domestic and international markets, which positions it favorably against competitors in the rapidly growing bio-chemical sector.
Zhejiang Dayang generates revenue through the sale of bio-based chemicals, which are increasingly in demand due to environmental regulations favoring sustainable products. The company benefits from strong pricing power due to its proprietary production processes and established customer relationships, particularly in the feed and food industries.
Fluctuations in raw material prices, particularly corn and sugar, which impact production costs.
Regulatory changes favoring bio-based products, enhancing demand.
Growth in the animal feed market, particularly in Asia, which is a key consumer of amino acids.
Expansion into international markets, particularly in Europe and North America.
Technological disruption in bio-chemical production processes.
Regulatory changes that could impose stricter environmental standards.
Emergence of new competitors in the bio-chemical space, particularly from countries with lower production costs.
Potential price wars due to increased competition in the amino acids market.
Moderate liquidity risk due to current ratio of 1.23, which may limit flexibility in capital allocation.
Potential exposure to currency fluctuations given international sales.
moderate - The company is somewhat sensitive to economic cycles, as demand for chemicals can fluctuate with industrial activity and consumer spending.
Rising interest rates could increase financing costs for expansion projects, potentially impacting growth plans and valuation multiples.
minimal - The company maintains a conservative debt profile with a Debt/Equity ratio of 0.44, reducing reliance on credit markets.
growth - Investors seeking exposure to the expanding bio-chemical sector and sustainable products.
moderate - Historical volatility is consistent with industry peers, reflecting both growth potential and market risks.
